Feed aggregator

Safety Issue Trips Third Harmonic Months After IPO

Biospace news - Thu, 12/15/2022 - 02:00
Third Harmonic Bio drops its Phase 1b asset.

AbCellera Continues Partnership Frenzy with AbbVie Antibody Discovery Pact

Biospace news - Thu, 12/15/2022 - 02:00
AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.

BioCryst Discontinues Mid-Stage Factor D Inhibitor

Biospace news - Thu, 12/15/2022 - 02:00
BioCryst Pharmaceuticals is discontinuing the development of its Factor D inhibitor BCX9930 in paroxysmal nocturnal hemoglobinuria due to competitive factors.

Senolytic Therapies Pose Revolutionary Potential to Roll Back Diseases of Aging

Biospace news - Thu, 12/15/2022 - 02:00
While showing early promise, Senolytics is a new field and most of the research is still in academic centers – most notably, the Mayo Clinic.

The 5 Most Affordable Cities for Biopharma Jobs in the US

Biospace news - Thu, 12/15/2022 - 02:00
If you want to maximize your career earnings, it pays to consider which cities are the most affordable. Here are the top five most affordable cities for biopharma in the U.S.

BioSpace Layoff Tracker 2022: Axcella Therapeutics, TherapeuticsMD, Instil Bio and More Cull Staff

Biospace news - Thu, 12/15/2022 - 02:00
The layoffs trend in the life sciences industry is continuing into the final months of 2022. See inside for details on which companies are reducing staff to increase cash flow.

Drug discovery offers potential treatment for common kidney disease

World Pharma News - Wed, 12/14/2022 - 11:00
A serious condition that can cause the kidneys to suddenly stop working could be treated with existing medicines, a new study shows.

In a study in mice scientists found that medicines usually used to treat angina and high blood pressure prevented much of the long-term damage to the kidney and cardiovascular system caused by acute kidney injury (AKI).

First Protein Degrader Tested Outside Oncology Yields Promising Results

Biospace news - Wed, 12/14/2022 - 02:00
Kymera and Sanofi shared positive results for an IRAK4 degrader for hidradenitis suppurativa and atopic dermatitis.

BeiGene’s Brukinsa Outshines Janssen’s Imbruvica in Comparison Trial

Biospace news - Wed, 12/14/2022 - 02:00
In a comparison trial, BeiGene’s Brukinsa bested Janssen’s Imbruvica in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).

Vertex and SpliSense Tackle CF with Novel Inhaled mRNA Approaches

Biospace news - Wed, 12/14/2022 - 02:00
Vertex is kicking off a Phase I trial assessing VX-522, an mRNA therapy designed to treat the underlying cause of cystic fibrosis lung disease, while SpliSense is targeting a specific mutation.

Avidity Biosciences Stock Soars On New RNA Data

Biospace news - Wed, 12/14/2022 - 02:00
Shares of Avidity Biosciences are soaring following reported early signs of clinical activity and improvement in patients with myotonic dystrophy type 1 (DM1) treated with its RNA-based therapeutic.

Will the Popularity of Remote Work Sustain Through 2023?

Biospace news - Wed, 12/14/2022 - 02:00
The past two years have seen a considerable shift towards remote work, but now that the pandemic is waning, BioSpace has compiled relevant data on remote work to see if it's here to stay.

GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets

World Pharma News - Tue, 12/13/2022 - 13:00
GSK plc (LSE/NYSE: GSK) and Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing programme targeting alpha-1 antitrypsin deficiency (AATD), WVE-006.

Moderna and Merck’s mRNA Cancer Vaccine Aces Advanced Melanoma Study (Updated)

Biospace news - Tue, 12/13/2022 - 02:00
​​​​​​​An investigational mRNA cancer vaccine developed by Moderna and Merck reached its primary efficacy endpoint, inducing a clinically meaningful improvement in recurrence-free survival.

GSK Strikes $3.3B Oligonucleotide Pact with Wave Life Sciences

Biospace news - Tue, 12/13/2022 - 02:00
GSK bolstered its position in the oligonucleotide therapeutics space through a four-year collaboration with Wave Life Sciences valued at up to $3.3 billion.

Takeda Bets $4B Upfront on Nimbus' TYK2 Inhibitor

Biospace news - Tue, 12/13/2022 - 02:00
On the heels of positive Phase IIb data in plaque psoriasis, Takeda is acquiring both the therapy and Nimbus Lakshmi, a wholly owned subsidiary, in a potentially $6 billion deal.

Flagship-Backed Biotech Uses Naturally-Occurring Molecules to Treat Chronic Disease (Updated)

Biospace news - Tue, 12/13/2022 - 02:00
Flagship Pioneering has committed $50 million to Montai Health, a biotech that aims to develop therapies for chronic diseases using molecules already found in nature.

Novel Capabilities of Innovative AntibodyPlus Therapeutics Go Beyond ADCs

Biospace news - Tue, 12/13/2022 - 02:00
Developed initially to deliver cytotoxic payloads to tumors, antibody therapeutics are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer.

Cover Letter Do's and Don’ts

Biospace news - Tue, 12/13/2022 - 02:00
To help you in your job search, we've compiled a list of cover letter do's and don'ts.